Sphera Funds Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.58M Buy
30,256
+5,000
+20% +$1.11M 1.05% 35
2025
Q4
$5.77M Hold
25,256
1.12% 37
2025
Q3
$5.85M Hold
25,256
1.23% 23
2025
Q2
$4.69M Sell
25,256
-5,000
-17% -$929K 1.1% 29
2025
Q1
$6.34M Sell
30,256
-4,000
-12% -$778K 1.46% 17
2024
Q4
$6.09M Sell
34,256
-3,744
-10% -$688K 1.1% 30
2024
Q3
$7.5M Hold
38,000
1.19% 28
2024
Q2
$6.52M Hold
38,000
0.89% 38
2024
Q1
$6.92M Sell
38,000
-8,000
-17% -$1.38M 0.97% 36
2023
Q4
$7.13M Hold
46,000
1.15% 31
2023
Q3
$6.86M Sell
46,000
-10,000
-18% -$1.47M 1.25% 24
2023
Q2
$7.54M Sell
56,000
-7,000
-11% -$1.03M 1.18% 26
2023
Q1
$10M Buy
63,000
+3,000
+5% +$459K 1.68% 17
2022
Q4
$9.7M Sell
60,000
-102,285
-63% -$15.7M 2.08% 11
2022
Q3
$21.8M Sell
162,285
-56,100
-26% -$8.05M 3.02% 8
2022
Q2
$33.4M Buy
218,385
+27,391
+14% +$4.19M 3.58% 7
2022
Q1
$31M Sell
190,994
-273,200
-59% -$39.7M 4.38% 5
2021
Q4
$62.9M Sell
464,194
-132,100
-22% -$15.6M 6.91% 1
2021
Q3
$64.3M Buy
596,294
+230,100
+63% +$26.3M 5.4% 3
2021
Q2
$41.2M Sell
366,194
-233,306
-39% -$26.3M 2.79% 11
2021
Q1
$64.9M Buy
599,500
+259,500
+76% +$27.8M 4.98% 3
2020
Q4
$36.4M Sell
340,000
-450,000
-57% -$43.2M 3.23% 8
2020
Q3
$69.2M Buy
790,000
+55,402
+8% +$5.22M 6.8% 2
2020
Q2
$72.1M Buy
734,598
+569,598
+345% +$50.2M 6.78% 2
2020
Q1
$12.6M Buy
+165,000
New +$14.1M 1.57% 15
2016
Q1
Sell
-362,000
Closed -$21.4M 90
2015
Q4
$21.4M Buy
362,000
+35,000
+11% +$2.02M 3.14% 8
2015
Q3
$17.8M Sell
327,000
-80,000
-20% -$5.21M 2.27% 10
2015
Q2
$27.3M Hold
407,000
2.68% 7
2015
Q1
$23.8M Buy
+407,000
New +$24.6M 2.48% 8
2014
Q4
Sell
-403,550
Closed -$23.3M 126
2014
Q3
$23.3M Buy
+403,550
New +$22.4M 2.88% 8

Other funds holding ABBV

Sphera Funds Management's ABBV Position: Q1 2026 in Review

Sphera Funds Management increased its AbbVie (ABBV) stake by 20% in Q1 2026, buying an estimated $1.11M and bringing the position to 30,256 shares worth $6.58M. The position accounts for 1.05% of the portfolio, ranked #35.

Sphera Funds Management first reported a position in ABBV in Q3 2014 and has held it in 30 quarters since. The position peaked at $72.1M in Q2 2020. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Sphera Funds Management held 30,256 shares of AbbVie worth $6.58M as of Q1 2026.
  • Sphera Funds Management bought 5,000 AbbVie shares in Q1 2026, an estimated $1.11M.
  • AbbVie made up 1.05% of Sphera Funds Management's portfolio in Q1 2026, its #35 holding.
  • Sphera Funds Management first reported a position in AbbVie in Q3 2014 and has held it in 30 quarters since.
  • Sphera Funds Management's AbbVie position peaked at $72.1M in Q2 2020.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.